Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Authors
Keywords
-
Journal
Nature Reviews Nephrology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-10
DOI
10.1038/s41581-022-00535-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
- (2021) Taha Sen et al. Cell Metabolism
- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial
- (2021) Nan Ye et al. CIRCULATION
- Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria
- (2021) Meg Jardine et al. Clinical Journal of the American Society of Nephrology
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
- (2021) David Z. I. Cherney et al. DIABETOLOGIA
- Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
- (2021) Shruti S Joshi et al. HEART
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
- (2021) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- Cardiovascular Disease in Chronic Kidney Disease
- (2021) Joachim Jankowski et al. CIRCULATION
- Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation
- (2021) Hiddo J. L. Heerspink et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
- (2021) Husam Ghanim et al. DIABETES OBESITY & METABOLISM
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
- (2021) João Pedro Ferreira et al. Journal of the American Heart Association
- Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
- (2021) Michael Szarek et al. ANNALS OF INTERNAL MEDICINE
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Milton Packer et al. CIRCULATION
- Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
- (2021) Frederik Persson et al. DIABETES CARE
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
- (2021) Scott D. Solomon et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
- (2021) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
- (2021) Hiddo JL. Heerspink et al. KIDNEY INTERNATIONAL
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Major Renal Outcomes in Heart Failure
- (2021) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
- (2021) John J.V. McMurray et al. JACC-Heart Failure
- Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
- (2021) Hiddo J.L. Heerspink et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients
- (2020) Fatima AlKindi et al. TRANSPLANTATION PROCEEDINGS
- Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
- (2020) Christie Rampersad et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study
- (2020) Carina Iskander et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
- (2020) Meg J. Jardine et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
- (2020) Alice M. Jackson et al. CIRCULATION
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements ( SCREAM ) Project
- (2020) Junichi Ishigami et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- P1003STUDY DESIGN OF THE ROTATION FOR OPTIMAL TARGETING OF ALBUMINURIA AND TREATMENT EVALUATION (ROTATE-3): A ROTATION STUDY OF DIFFERENT ALBUMINURIA LOWERING DRUGS CLASSES TO STUDY INDIVIDUAL DRUG RESPONSE IN DIABETIC AND NON-DIABETIC CKD
- (2020) Michele Provenzano et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
- (2020) Scott D. Solomon et al. JACC-Heart Failure
- Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
- (2020) Brendon L. Neuen et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
- (2020) Adeera Levin et al. Clinical Journal of the American Society of Nephrology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
- (2020) Matthew R Weir et al. Clinical Kidney Journal
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
- (2020) Silvio E. Inzucchi et al. DIABETES CARE
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
- (2020) Milton Packer et al. EUROPEAN HEART JOURNAL
- Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
- (2020) Megumi Oshima et al. KIDNEY INTERNATIONAL
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
- (2020) Ashish Sarraju et al. AMERICAN HEART JOURNAL
- Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
- (2020) Dora Oikonomaki et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
- (2020) Bettina J. Kraus et al. KIDNEY INTERNATIONAL
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
- (2019) Thea Anine Strøm Halden et al. DIABETES CARE
- Hypertension in CKD: Core Curriculum 2019
- (2019) Elaine Ku et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
- (2019) Motoaki Sano et al. CIRCULATION
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
- (2019) Takashi Maruyama et al. Diabetes Technology & Therapeutics
- How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- (2019) Burkert Pieske et al. EUROPEAN HEART JOURNAL
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
- (2019) Brendon L. Neuen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Testosterone Increases the Expression and Phosphorylation of AMP kinase α in Men with Hypogonadism and Type 2 Diabetes
- (2019) Husam Ghanim et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
- (2019) Jan Menne et al. PLOS MEDICINE
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- (2018) Motoaki Sano Journal of Cardiology
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation
- (2016) Jozine M. ter Maaten et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- The kidney in heart failure: an update
- (2015) Kevin Damman et al. EUROPEAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
- (2015) Kunihiro Matsushita et al. Lancet Diabetes & Endocrinology
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Notice
- (2012) Kidney International Supplements
- Systolic Heart Failure
- (2010) John J.V. McMurray NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now